Identification and management of heterozygous familial hypercholesterolemia: summary and recommendations from an NHLBI workshop.
Am J Cardiol
; 72(10): 1D-5D, 1993 Sep 30.
Article
em En
| MEDLINE
| ID: mdl-8105671
ABSTRACT
Heterozygous familial hypercholesterolemia (hFH) is one of the most common monogenic disorders with serious health consequences, affecting approximately 1 in 500 persons in the United States. Persons with hFH generally manifest elevations of low density lipoprotein (LDL) cholesterol throughout their lives and have a markedly increased risk of death from coronary artery disease. The hypercholesterolemia of hFH is responsive to medication and diet, and, if detected early, aggressive LDL cholesterol control may prevent or substantially delay cardiovascular disease. However, evidence suggests that many persons with hFH are undetected and inadequately treated. On July 20-21, 1992, the National Heart, Lung, and Blood Institute sponsored a workshop to assess the current understanding of the diagnosis and management of hFH, to emphasize recommendations for identification and management that are known to be effective, and to identify opportunities and needs for intervention and research.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Hiperlipoproteinemia Tipo II
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
1993
Tipo de documento:
Article